OTSSP167
Based on 23 publication(s) in Google Scholar
OTSSP167 (OTS167) is a highly potent and ATP-competitive MELK inhibitor with IC50 value of 0.41 nM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.27%
- CAS No.: 1431697-89-0
- Formule: C25H28Cl2N4O2
- Masse moléculaire:487.42
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) OTSSP167
More- Mol Cancer. 2014 May 4;13:100. [Abstract]
- Nat Cancer. 2024 Aug;5(8):1250-1266. [Abstract]
- Blood Cancer J. 2019 Nov 18;9(12):87. [Abstract]
- Neuro Oncol. 2020 Jan 11;22(1):58-69. [Abstract]
- Clin Cancer Res. 2018 Nov 15;24(22):5645-5657. [Abstract]
- Free Radic Biol Med. 2021 Aug 20:172:312-329. [Abstract]
- EMBO Mol Med. 2018 Mar;10(3). pii: e8274. [Abstract]
- Int J Oncol. 2022 Jul;61(1):89. [Abstract]
- Eur J Pharmacol. 2025 Oct 5:1004:178017. [Abstract]
- Int J Mol Sci. 2025 Mar 3;26(5):2245. [Abstract]
- Sci Rep. 2017 Feb 14;7:42502. [Abstract]
- Gynecol Oncol. 2017 Apr;145(1):159-166. [Abstract]
- FEBS J. 2026 Feb 2. [Abstract]
- Adv Ther (Weinh). 2025 Oct 24.
- PLoS One. 2017 Feb 24;12(2):e0172832. [Abstract]
- Biochem Biophys Res Commun. 2014 Apr 25;447(1):7-11. [Abstract]
- bioRxiv. 2026 Apr 24.
- University of Washington. 2025.
- Elife. 2018 Feb 8;7:e32838. [Abstract]
- Oncotarget. 2017 Dec 20;9(2):2591-2602. [Abstract]
- Elife. 2017 Mar 24;6:e24179. [Abstract]
- Patent. US20160291017A1.
- Oncotarget. 2016 Feb 2;7(5):6266-80. [Abstract]
Customer Validation & Images
-
WB
-
WB
-
WB
-
IP
-
WB
Activité biologique
IC50: 0.41 nM (MELK)
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 769-P | IC50 |
20.1 nM
Compound: OTS167
|
Cytotoxicity against human 769-P cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human 769-P cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| 786-0 | IC50 |
23.9 nM
Compound: OTS167
|
Cytotoxicity against human 786-O cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human 786-O cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| A549 | IC50 |
6.7 nM
Compound: OTS167
|
Antiproliferative activity against human A549 cells
Antiproliferative activity against human A549 cells
|
[PMID: 30108692] |
| BGC-823 | IC50 |
25 nM
Compound: OTS167
|
Antiproliferative activity against human BGC823 cells after 24 to 96 hrs by CCK8 assay
Antiproliferative activity against human BGC823 cells after 24 to 96 hrs by CCK8 assay
|
[PMID: 30108692] |
| CAKI-1 | IC50 |
12.4 nM
Compound: OTS167
|
Cytotoxicity against human Caki1 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human Caki1 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| CAKI-2 | IC50 |
38.7 nM
Compound: OTS167
|
Cytotoxicity against human Caki2 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human Caki2 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| CWR22R | IC50 |
6 nM
Compound: OTS167
|
Antiproliferative activity against human 22Rv1 cells
Antiproliferative activity against human 22Rv1 cells
|
[PMID: 30108692] |
| DMS-114 | IC50 |
2.1 nM
Compound: OTS167
|
Cytotoxicity against human DMS114 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human DMS114 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| DMS-273 | IC50 |
8.4 nM
Compound: OTS167
|
Cytotoxicity against human DMS273 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human DMS273 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| DU-4475 | IC50 |
2.3 nM
Compound: OTS167
|
Antiproliferative activity against human DU4475 cells
Antiproliferative activity against human DU4475 cells
|
[PMID: 30108692] |
| HEK-293T | CC50 |
64 nM
Compound: 5; OTS167
|
Cytotoxicity against human HEK293T cells transfected with DYRK1A co-tranfected with Renilla plasmid, pGL3-NFAT and NFATc1 assessed as reduction in luciferase activity by measuring cell number
Cytotoxicity against human HEK293T cells transfected with DYRK1A co-tranfected with Renilla plasmid, pGL3-NFAT and NFATc1 assessed as reduction in luciferase activity by measuring cell number
|
[PMID: 31757680] |
| HEK-293T | EC50 |
5 nM
Compound: 5; OTS167
|
Inhibition of human DYRK1A transfected in HEK293T cells co-transfected with Renilla plasmid, pGL3-NFAT and NFATc1 assessed as derepression of NFAT-dependent luciferase activity measured after 48 hrs by luciferase assay
Inhibition of human DYRK1A transfected in HEK293T cells co-transfected with Renilla plasmid, pGL3-NFAT and NFATc1 assessed as derepression of NFAT-dependent luciferase activity measured after 48 hrs by luciferase assay
|
[PMID: 31757680] |
| K562 | IC50 |
33 nM
Compound: OTS167
|
Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 30108692] |
| KG-1 | IC50 |
16.9 nM
Compound: OTS167
|
Cytotoxicity against human KG1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human KG1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 30108692] |
| KG-1a | IC50 |
26.4 nM
Compound: OTS167
|
Cytotoxicity against human KG1a cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human KG1a cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 30108692] |
| ML-2 | IC50 |
33.8 nM
Compound: OTS167
|
Cytotoxicity against human ML2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human ML2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 30108692] |
| MOLM-13 | IC50 |
17.5 nM
Compound: OTS167
|
Cytotoxicity against human MOLM13 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MOLM13 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 30108692] |
| MV4-11 | IC50 |
7.9 nM
Compound: OTS167
|
Cytotoxicity against human MV4-11 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MV4-11 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 30108692] |
| NCI-H146 | IC50 |
7.9 nM
Compound: OTS167
|
Cytotoxicity against human NCI-H146 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human NCI-H146 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| NCI-H2171 | IC50 |
4.7 nM
Compound: OTS167
|
Cytotoxicity against human NCI-H2171 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human NCI-H2171 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| NCI-H446 | IC50 |
6.2 nM
Compound: OTS167
|
Cytotoxicity against human NCI-H446 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human NCI-H446 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| NCI-H524 | IC50 |
1.9 nM
Compound: OTS167
|
Cytotoxicity against human NCI-H524 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human NCI-H524 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| NCI-H69 | IC50 |
0.8 nM
Compound: OTS167
|
Cytotoxicity against human H69 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human H69 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| NCI-H82 | IC50 |
1.7 nM
Compound: OTS167
|
Cytotoxicity against human H82 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human H82 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| SBC-3 | IC50 |
4.3 nM
Compound: OTS167
|
Cytotoxicity against human SBC3 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human SBC3 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| SBC-5 | IC50 |
2.8 nM
Compound: OTS167
|
Cytotoxicity against human SBC5 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human SBC5 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108692] |
| SGC-7901 | IC50 |
25 nM
Compound: OTS167
|
Antiproliferative activity against human SGC7901 cells after 24 to 96 hrs by CCK8 assay
Antiproliferative activity against human SGC7901 cells after 24 to 96 hrs by CCK8 assay
|
[PMID: 30108692] |
| T47D | IC50 |
4.3 nM
Compound: OTS167
|
Antiproliferative activity against human T47D cells
Antiproliferative activity against human T47D cells
|
[PMID: 30108692] |
| THP-1 | IC50 |
15.6 nM
Compound: OTS167
|
Cytotoxicity against human THP1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human THP1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 30108692] |
| U-937 | IC50 |
69.8 nM
Compound: OTS167
|
Cytotoxicity against human U937 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human U937 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 30108692] |
OTSSP167 inhibits the growth of A549 (lung), T47D (breast), DU4475 (breast), 22Rv1 (prostate) and HT1197 (bladder) cancer cells with IC50 values of 6.7, 4.3, 2.3, 6.0 and 97 nM, respectively[1]. OTSSP167 can abrogate the mitotic checkpoint, disrupt MCC and MCC-APC/C interaction in MCF7 cells. OTSSP167 causes GFP-MELK localization to cell cortex in prometaphase cells[2]. OTSSP167 is a MELK selective inhibitor, exhibits a strong in vitro activity, conferring an IC50 of 0.41 nM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1431697-89-0
-
Appearance Solid
-
Masse moléculaire 487.42
-
Formule C25H28Cl2N4O2
-
Color Light yellow to yellow
-
SMILES
ClC1=CC(C2=CC=C(N=CC(C(C)=O)=C3N[C@H]4CC[C@H](CN(C)C)CC4)C3=N2)=CC(Cl)=C1O
-
Synonyms
OTS167
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (23)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway. [Abstract]2014 May 4;13:100. PMID: 24885567
OTSSP167 purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2014 May 4;13:100. [Abstract]
MELK specific inhibitor OTSSP167 suppresses cell migration and invasion. A, Immunoblotting representing MELK expression in SGC7901 cell following OTSSP167 treatment for indicated period. In the upper panel, SGC7901 cell are treated with different concentration (0, 0.1, 1 μM) of OTSSP167 for 1 h and 2 h. In the lower panel, SGC7901/vector and SGC7901/MELK cell are treated with 1 μM OTSSP167 for 2 h. C, SGC7901/vector and SGC7901/MELK cells are treated with 1 μM OTSSP167 for indicated period and
-
Nat Cancer
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance. [Abstract]2024 Aug;5(8):1250-1266. PMID: 38992135 -
Blood Cancer J
Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma. [Abstract]2019 Nov 18;9(12):87. PMID: 31740676
OTSSP167 purchased from MedChemExpress. Usage Cited in: Blood Cancer J. 2019 Nov 18;9(12):87. [Abstract]
Expression of MELK and Aurora B kinase (AurB) is determined in samples from vehicle and OTSSP167-treated mice. β-actin is used as loading control.
-
Neuro Oncol
MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors. [Abstract]2020 Jan 11;22(1):58-69. PMID: 31504799 -
Clin Cancer Res
2018 Nov 15;24(22):5645-5657. PMID: 30061363
OTSSP167 purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2018 Nov 15;24(22):5645-5657. [Abstract]
Western blot showing protein levels of MELK, PPARγ and phospho-PPARγS112 in JHH-DIPG-01, HSJD-DIPG-12, SF7761 and HSJD-DIPG-07 cells after 48 hours treatment with either 20 nM or 50 nM OTSSP167.
-
Free Radic Biol Med
Pharmacological inhibition of MELK restricts ferroptosis and the inflammatory response in colitis and colitis-propelled carcinogenesis. [Abstract]2021 Aug 20:172:312-329. PMID: 34144192 -
EMBO Mol Med
Identification of potential therapeutic targets in prostate cancer through a cross-species approach. [Abstract]2018 Mar;10(3). pii: e8274. PMID: 29437778
OTSSP167 purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2018 Mar;10(3). pii: e8274. [Abstract]
Validation of effects of OTS167 on phosphorylation of p90RSK and its targets. C4-2b cells are treated with vehicle or 30 nM OTS167 for the indicated times, and levels of total and phosphorylated proteins are determined by Western blot analysis. β-Actin is used as a loading control.
-
Int J Oncol
Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines. [Abstract]2022 Jul;61(1):89. PMID: 35642662 -
Eur J Pharmacol
2025 Oct 5:1004:178017. PMID: 40744390 -
Int J Mol Sci
2025 Mar 3;26(5):2245. PMID: 40076867 -
Sci Rep
Zinc finger protein ZPR9 functions as an activator of AMPK-related serine/threonine kinase MPK38/MELK involved in ASK1/TGF-β/p53 signaling pathways. [Abstract]2017 Feb 14;7:42502. PMID: 28195154
OTSSP167 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2017 Feb 14;7:42502. [Abstract]
In vitro kinase assays are performed using MPK38 immunoprecipitates, which are obtained from cell lysates of wild-type and clonal CRISPR/Cas9 ZPR9 (T252A) KI isolates, treated with (+) or without (−) OTSSP167 (1 μM, 2 h), a MPK38-specific inhibitor, in the presence of ZPR9 immunoprecipitates as the substrate. Recombinant MPK38 proteins (lower panels), which were expressed in bacterial cells, treated with (+) or without (−) OTSSP167 are also used instead of the MPK38 immunoprecipitates (upper pan
-
Gynecol Oncol
MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells. [Abstract]2017 Apr;145(1):159-166. PMID: 28214016
OTSSP167 purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2017 Apr;145(1):159-166. [Abstract]
Western blotting demonstrates that 100 nM OTSSP167 for 48 h produces marked PARP-1 cleavage in HGSOC cell lines whereas no or weak PARP-1 cleavage is observed in normal ovarian surface epithelial cells (HOSE6-3) and in the fallopian tubal cells (FT33-tag, FT190, FT237).
-
FEBS J
Nemo-like kinase modulates glucocorticoid-induced erythroid progenitor differentiation by regulating stability of the glucocorticoid receptor. [Abstract]2026 Feb 2. PMID: 41629744 -
-
PLoS One
Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant. [Abstract]2017 Feb 24;12(2):e0172832. PMID: 28235006
OTSSP167 purchased from MedChemExpress. Usage Cited in: PLoS One. 2017 Feb 24;12(2):e0172832. [Abstract]
OTS167 reduces proliferation and regulates MELK transcript but not protein levels in TNBC cells. The MELK 52 kDa variant is highly expressed in the TNBC cell lines but not in luminal A MCF-7.
-
Biochem Biophys Res Commun
The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor. [Abstract]2014 Apr 25;447(1):7-11. PMID: 24657156 -
-
-
Elife
MELK expression correlates with tumor mitotic activity but is not required for cancer growth. [Abstract]2018 Feb 8;7:e32838. PMID: 29417930 -
Oncotarget
2017 Dec 20;9(2):2591-2602. PMID: 29416794
OTSSP167 purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Dec 20;9(2):2591-2602. [Abstract]
Effects of OTSSP167 on PARP and Caspase-3 cleavages in NB cells are shown by immunoblotting assay.
-
Elife
CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. [Abstract]2017 Mar 24;6:e24179. PMID: 28337968 -
OTSSP167 purchased from MedChemExpress. Usage Cited in: Patent. US20160291017A1.
Mitotic MDA-MB-468 cells are treated for 30 min with vehicle or 200 nM OTSSP167, a MELK inhibitor. Lysates are used for immunoblotting.
-
Oncotarget
Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in gastric cancer. [Abstract]2016 Feb 2;7(5):6266-80. PMID: 26701722
Solvant et solubilité
DMSO : 2.5 mg/mL (5.13 mM; ultrasonic and warming and adjust pH to 4 with 1M HCl and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 2.5 mg/mL (5.13 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Protocole
For in vitro kinase assay, MELK recombinant protein (0.4 μg) is mixed with 5 μg of each substrate in 20 μL of kinase buffer containing 30 mM Tris-HCl (pH), 10 mM DTT, 40 mM NaF, 10 mM MgCl2, 0.1 mM EGTA with 50 μM cold-ATP and 10 Ci of [γ-32P]ATP for 30 min at 30°C. The reaction Is terminated by addition of SDS sample buffer and boiled for 5 min prior to SDS-PAGE. The gel is dried and autoradiographed with intensifying screens at room temperature. OTSSP167 (final concentration of 10 nM) is dissolved in DMSO and added to kinase buffer before the incubation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In vitro cell viability is measured by the colorimetric assay using Cell Counting Kit-8. Cells are plated in 100 μL in 96-well plates at a density that generates continual linear growth (A549, 1×103 cells; T47D, 3×103 cells; DU4475, 4×103 cells; 22Rv1, 6×103 cells; and HT1197, 2×103 cells, in 100 μL per well). The cells are allowed to adhere overnight before exposure to OTSSP167 for 72 hours at 37°C. Plates are read using a spectrophotometer at a wavelength of 450 nm. All assays are carried out in triplicate.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MDA-MB-231 cells are injected into the mammary fat pads of NOD.CB17-Prkdcscid/J mice. A549, MIAPaCa-2 and PC-14 cells (1×105 cells) are injected subcutaneously in the left flank of female BALB/cSLC-nu/nu mice. DU145 cells are injected subcutaneously in the left flank of male BALB/cSLC-nu/nu mice. When MDA-MB-231, A549, DU145, MIAPaCa-2, and PC-14 xenografts has reached an average volume of 100, 210, 110, 250, and 250 mm3, respectively, animals are randomized into groups of 6 mice (except for PC-14, for which groups of 3 mice are used). For oral administration, OTSSP167 and other compounds are prepared in a vehicle of 0.5% methylcellulose and given by oral garbage at the indicated dose and schedule. For intravenous administration, compounds are formulated in 5% glucose and injected into the tail vein. An administration volume of 10 mL per kg of body weight is used for both administration routes. Tumor volumes are determined every other day using a caliper.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Chung S, Suzuki H, Miyamoto T, et al. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec 21. [Content Brief]
[2]. Li S, et al. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in gastric cancer. Oncotarget. 2016 Feb 2;7(5):6266-80. [Content Brief]
[3]. Ji W, et al. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases. PLoS One. 2016 Apr 15;11(4):e0153518. [Content Brief]
[4]. Cho YS, et al. The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor. Biochem Biophys Res Commun. 2014 Apr 25;447(1):7-11. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0516 mL | 10.2581 mL | 20.5162 mL | 51.2905 mL |
| 5 mM | 0.4103 mL | 2.0516 mL | 4.1032 mL | 10.2581 mL |
OTSSP167 Related Classifications
HY-15512 Related Classifications
Powered by Bioz